AbbVie 3Q Revenue Rises on Strength in Immunology, Neuroscience

What happened

AbbVie said third-quarter revenue rose 10% to $17.4 billion, helped by higher sales of immunology and neuroscience drugs. The company raised its full-year profit outlook and its quarterly dividend, and both the quarterly results and guidance beat Wall Street expectations.

Confirmed

Global impact / market context

Faster sales of immunology drugs such as Skyrizi and Rinvoq, plus strong neuroscience growth, lift AbbVie's revenue and profit, which can support the higher dividend and give investors more confidence in future earnings and cash available.

Analyst inference

Beating analyst estimates and raising guidance signals stronger demand than expected, which may lead investors to value AbbVie's future profits more highly. Weak aesthetics revenue and flat oncology show growth is concentrated in immunology and neuroscience.

Analyst inference

What to watch

1. Full-year adjusted earnings per share are now projected at $13.95 to $13.99, up from the earlier $13.76 to $13.96 range, so watch whether later results stay within this raised outlook. Confirmed
2. Watch whether immunology sales keep growing at a double-digit pace as Skyrizi and Rinvoq take over from Humira, which is facing competition from cheaper copies. Proposed
3. Watch aesthetics and oncology revenue for signs of recovery, since a 1.4% decline in aesthetics and a 0.8% oncology gain mean growth depends heavily on two drug areas. Analyst inference

Evidence

• Original source link unavailable